Lifeward Sales Fall 15%, Miss Forecast

Lifeward (NASDAQ:LFWD), a developer of mobility and rehabilitation medical devices, released its second quarter 2025 earnings results on August 14, 2025. The company reported non-GAAP earnings per share of ($0.31), missing expectations of ($0.29), with revenue (GAAP) at $5.7 million, below the anticipated $6.69 million and the prior-year figure of $6.7 million. The revenue decline reflects the absence of $0.7 million in one-time Medicare-related catch-up revenue present in Q2 2024. Lifeward’s gross margin (non-GAAP) was 44.0%, slightly below last year’s 46.9%. Operating and net losses narrowed modestly, driven by cost controls, but the company remains significantly loss-making. Overall, the quarter showed operational improvements, particularly in pipeline expansion and regulatory progress, but persistent non-GAAP losses and the GAAP revenue miss weighed on results. Management revised full-year 2025 guidance to $24–$26 million in revenue and a non-GAAP net loss of $12–$14 million.

Source: Lifeward. Note: Analyst estimates provided by FactSet.

Lifeward develops, manufactures, and markets medical devices aimed at improving mobility for people with physical disabilities, particularly those with spinal cord injuries or neurological conditions. Its product lineup includes the ReWalk Personal Exoskeleton, a wearable robotic device that allows those with lower-limb disabilities to walk, the MyoCycle Therapy System for functional electrical stimulation (FES) cycling, and the AlterG Anti-Gravity system, which is used in rehabilitation to reduce effective body weight during walking or running.

Continue reading

Source Fool.com